<DOC>
	<DOC>NCT01096849</DOC>
	<brief_summary>Multi-center, multi-national, double-blind, randomized, comparator-controlled study of plazomicin administered intravenously compared with levofloxacin, a standard approved intravenous therapy for complicated urinary tract infection (cUTI) and acute pyelonephritis (AP).</brief_summary>
	<brief_title>Study of Plazomicin (ACHN-490) Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>cUTI/AP with clinical signs and symptoms Normal kidney function Patients with any of the following conditions: underlying renal disease (excluding indication cUTI/AP), myasthenia gravis,or other neuromuscular disorder. Urinary tract surgery during the study period. Signs of severe sepsis. Pregnant or breastfeeding women. History of epilepsy or known seizure disorder. Receipt of any investigational medication during the last month prior to randomization. Treatment with another antibiotic within 48 hours prior to randomization. Known history of human immunodeficiency virus (HIV) infection and current or previous CD4 count &lt; 200/mm3. Presence of immunodeficiency or an immunocompromised condition and use of systemic corticosteroids. Presence of neutropenia. History of hearing loss with onset before the age of 40 years. At risk for serious drug interactions because of concomitant medications [e.g., class IA (e.g., quinidine, procainamide, or Class III (e.g, amiodarone, sotalol)antiarrhythmic agents] A QTc (Bazett's)&gt; 440 msec. Known hypersensitivity to other aminoglycosides, levofloxacin, other fluoroquinolone antibiotics.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>urinary tract infection</keyword>
	<keyword>UTI</keyword>
	<keyword>cUTI</keyword>
	<keyword>pyelonephritis</keyword>
	<keyword>AP</keyword>
	<keyword>ACHN-490</keyword>
</DOC>